Melphalan 200 mg/m2 versus melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study (vol 115, pg 1873, 2010)

被引：2
|
作者：
Palumbo, A.
Bringhen, S.
Bruno, B.
机构：
来源：
BLOOD | 2010年 / 116卷 / 12期
关键词：
D O I：
10.1182/blood.V116.21.1940.1940
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2195 / 2195
页数：1
相关论文
共 50 条
  • [1] Melphalan 200 mg/m2 versus melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study
    Palumbo, Antonio
    Bringhen, Sara
    Bruno, Benedetto
    Falcone, Antonietta Pia
    Liberati, Anna Marina
    Grasso, Mariella
    Ria, Roberto
    Pisani, Francesco
    Cangialosi, Clotilde
    Caravita, Tommaso
    Levi, Anna
    Meloni, Giovanna
    Nozza, Andrea
    Pregno, Patrizia
    Gabbas, Attilio
    Callea, Vincenzo
    Rizzo, Manuela
    Annino, Luciana
    De Stefano, Valerio
    Musto, Pellegrino
    Baldi, Ileana
    Cavallo, Federica
    Petrucci, Maria Teresa
    Massaia, Massimo
    Boccadoro, Mario
    [J]. BLOOD, 2010, 115 (10) : 1873 - 1879
  • [2] Melphalan 200 mg/m2 versus 100 mg/m2 in newly diagnosed myeloma
    Palumbo, A.
    Bringhen, S.
    Petrucci, M. T.
    Falcone, A.
    Liberati, A. M.
    Lauta, V. M.
    Montanaro, M.
    Cangialosi, C.
    Morandi, S.
    D'Agostino, F.
    Cavallo, F.
    Omede, P.
    Musto, P.
    Foue, R.
    Boccadoro, M.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 189 - 189
  • [3] A prospective, randomized, phase III study of melphalan 200 mg/m2 (Mel200) versus melphalan 100 mg/m2 (Mel100) in newly diagnosed myeloma patients
    Palumbo, Antonio
    Bringhen, Sara
    Petrucci, Maria Teresa
    Falcone, Antonietta
    Liberati, Anna Marina
    Lauta, Vito Michele
    Grasso, Mariella
    Montanaro, Marco
    Pisani, Francesco
    Caravita, Tommaso
    Cangialosi, Clotilde
    Pregno, Patrizia
    Nozza, Andrea
    Calabrese, Elisabetta
    Gay, Francesca
    Cavallo, Federica
    Omede, Paola
    Musto, Pellegrino
    Foa, Robin
    Boccadoro, Mario
    [J]. BLOOD, 2007, 110 (11) : 223A - 223A
  • [4] Melphalan 200 mg/m2 (MEL200) versus melphalan 100 mg/m2 (MEL100) in newly diagnosed myeloma patients:: A prospective, randomized phase III study
    Bringhen, S.
    Petrucci, M. T.
    Falcone, A.
    Liberati, A. M.
    Omede, P.
    Pregno, F.
    Nozza, A.
    Palmas, A.
    Capaldi, A.
    Callea, V
    De Stefano, V
    Annino, L.
    Siniscalchi, A.
    Avonto, I
    Cavallo, F.
    Musto, P.
    Foa, R.
    Boccadoro, M.
    Palumbo, A.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 2 - 2
  • [5] MELPHALAN 200 MG/M2 (MEL200) VERSUS MELPHALAN 100 MG/M2 (MEL100) IN NEWLY DIAGNOSED MYELOMA PATIENTS: A PROSPECTIVE, RANDOMIZED PHASE III STUDY
    Boccadoro, M.
    Bringhen, S.
    Petrucci, M. T.
    Falcone, A.
    Liberati, A. M.
    Morandi, S.
    Gabbas, A.
    Capaldi, A.
    Callea, V.
    De Stefano, V.
    Bongarzoni, V.
    Rizzo, M.
    Calabrese, E.
    Cavallo, F.
    Gay, F.
    Omede, P.
    Musto, P.
    Foa, R.
    Palumbo, A.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 364 - 364
  • [6] A prospective, randomized, phase III study of melphalan 200 mg/m2 (MEL200) versus melphalan 100 mg/m2 (MEL100) in newly diagnosed myeloma patients.
    Palumbo, Antonio
    Bringhen, Sara
    Petrucci, Maria Teresa
    Falcone, Antonietta
    Liberati, Anna Marina
    Grasso, Mariella
    Pisani, Francesco
    Caravita, Tommaso
    Pregno, Patrizia
    Nozza, Andrea
    Omede, Paola
    Falco, Patrizia
    Musto, Pellegrino
    Foa, Robin
    Boccadoro, Mario
    [J]. BLOOD, 2006, 108 (11) : 21A - 21A
  • [7] Melphalan 200 Mg/m2 (Me1200) Versus Melphalan 100 Mg/m2 (Me1100) in Newly Diagnosed Myeloma Patients: A Prospective, Randomized Phase III Study.
    Boccadoro, Mario
    Bringhen, Sara
    Petrucci, Maria Teresa
    Falcone, Antonietta
    Liberati, Anna Marina
    Ria, Roberto
    Grasso, Mariella
    Montanaro, Marco
    Pregno, Patrizia
    Nozza, Andrea
    Pisani, Francesco
    Caravita, Tommaso
    Cangialosi, Clotilde
    Calabrese, Elisabetta
    Larocca, Alessandra
    Cavallo, Federica
    Ruggeri, Marina
    Musto, Pellegrino
    Foa, Robert
    Palumbo, Antonio
    [J]. BLOOD, 2008, 112 (11) : 1139 - 1139
  • [8] Melphalan, prednisone, lenalidomide versus melphalan (200 mg/m2) and autologous transplantation in newly diagnosed myeloma patients: a phase III trial
    Palumbo, A.
    Cavallo, F.
    Nagler, A.
    Gay, F.
    Catalano, L.
    Baraldi, A.
    Galli, M.
    Pescosta, N.
    Cangialosi, C.
    Cascavilla, N.
    Benevolo, G.
    Ria, R.
    Rossi, D.
    Olivero, B.
    Guglielmelli, T.
    Gamberi, B.
    Redoglia, V.
    Di Toritto, T. Caravita
    Di Raimondo, F.
    Boccadoro, M.
    [J]. BONE MARROW TRANSPLANTATION, 2011, 46 : S38 - S38
  • [9] In myeloma patients treated with melphalan 100mg/m2 or melphalan 200mg/m2 outcome is not significantly different.
    Palumbo, A
    Triolo, S
    Bringhen, S
    Rus, C
    Omedè, P
    Bertola, A
    Giaccone, L
    Bianchi, A
    Bruno, B
    Tarella, C
    Caravita, T
    Musto, P
    Amadori, S
    Carotenuto, M
    Pileri, A
    Boccadoro, M
    [J]. BLOOD, 2000, 96 (11) : 419A - 419A
  • [10] Dose-intensive melphalan regimens (100 mg/m2 versus 200 mg/m2) in multiple myeloma patients.
    Boccadoro, M
    Bringhen, S
    Cavallo, F
    Falco, P
    Bertola, A
    Barbui, A
    Caravita, T
    Musto, P
    Pescosta, N
    Vignetti, M
    Palumbo, A
    [J]. BLOOD, 2002, 100 (11) : 431A - 431A
12345